Olaparib is a poly(ADP-ribose) polymerase inhibitor and cediranib is an anti-angiogenic agent with activity against VEGF receptor (VEGFR) 1, VEGFR2, and VEGFR3. A comment article notes that this trial is the first phase 2 evaluation assessing PARP inhibitors in combination with anti-angiogenic agents for patients with recurrent platinum-sensitive ovarian cancer and mutated, wild-type, or unknown BRCA status. The median PFS in the study is considered encouraging compared with that reported in trials using platinum-based chemotherapy with and without bevacizumab (median PFS 8.4–12.4 months). However, without results from larger phase 3 trials assessing PFS and overall survival, the toxicity of the combination remains an important issue as toxicity associated with its use was higher compared with olaparib alone. Whether the combination of olaparib and cediranib will safely replace platinum-based chemotherapy might be answered by findings from upcoming phase 3 trials of the combination against a platinum-based chemotherapy combination.